Core Viewpoint - The article highlights the significant advancements in the treatment of Amyotrophic Lateral Sclerosis (ALS), particularly through the efforts of patient advocate Cai Lei, who emphasizes the role of Chinese technology, national support, and community solidarity in achieving breakthroughs in drug development for this previously untreatable disease [1][9]. Group 1: Patient Advocacy and Research Efforts - Cai Lei, diagnosed with ALS in 2019, has dedicated himself to combating the disease, unlike many who choose to give up [3][4]. - He has faced challenges in securing funding for research, often encountering rejections, but remains determined to continue his efforts [6]. - In 2024, with support from various sectors, his team successfully advanced 10 drug candidates into clinical stages [6]. Group 2: Community and Support Initiatives - The "Jianyu Mutual Aid Home," initiated by Cai Lei, has reached 15,000 ALS patients, providing crucial support [6]. - Approximately 1,000 patients have signed up to donate their bodies and spinal cord tissues for research, showcasing a strong community commitment to finding a cure [8]. Group 3: Clinical Developments and Future Prospects - A drug targeting specific genetic types of ALS has entered Phase I clinical trials, marking a significant milestone in treatment options [9]. - Despite the progress, Cai Lei's specific genetic condition is not included in the current breakthroughs, highlighting the ongoing challenges faced by many patients [10]. Group 4: Recognition and Technological Integration - Cai Lei received the title of "National Self-Reliance Model," which he views as recognition not just for himself but for the entire ALS community [12]. - The integration of artificial intelligence in ALS research has led to the identification of new treatment targets and potential drugs, indicating a promising direction for future therapies [14].